CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval

Stock Information for CytoDyn Inc

Loading

Please wait while we load your information from QuoteMedia.